Search results
Results from the WOW.Com Content Network
Propranolol may cause harmful effects for the baby if taken during pregnancy; [7] however, its use during breastfeeding is generally considered to be safe. [8] It is a non-selective beta blocker which works by blocking β-adrenergic receptors. [2] Propranolol was patented in 1962 and approved for medical use in 1964. [9]
BMB-201 is a serotonin 5-HT 2A and 5-HT 2C receptor agonist described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications.
An anxiolytic (/ ˌ æ ŋ k s i ə ˈ l ɪ t ɪ k, ˌ æ ŋ k s i oʊ-/; also antipanic or anti-anxiety agent) [1] is a medication or other intervention that reduces anxiety.This effect is in contrast to anxiogenic agents which increase anxiety.
Inderal (propranolol) – a beta blocker; it is used for acute anxiety, panic attacks, and hypertension; Intuniv - an extended release, non-stimulant alpha-2 adrenergic agonist used to treat attention deficit hyperactivity disorder. Available in instant-release under the brand-name Tenex.
There is clear evidence from many controlled trials in the past 25 years that beta blockers are effective in anxiety disorders, though the mechanism of action is not known. [3] Some people have used beta blockers for performance type social anxiety, or "stage fright." In particular, musicians, public speakers, actors, and professional dancers ...
The companies claimed, among other things, that the health warnings violated their free speech rights by compelling the companies to endorse the U.S. government's anti-smoking message through ...
Figure 1: The chemical structure of dichloroisoprenaline or dichloroisoproterenol (), abbreviated DCI — the first β-blocker to be developed. β adrenergic receptor antagonists (also called beta-blockers or β-blockers) were initially developed in the 1960s, for the treatment of angina pectoris but are now also used for hypertension, congestive heart failure and certain arrhythmias. [1]
Karyn Hascal, The Healing Place’s president and CEO, said she would never allow Suboxone in her treatment program because her 12-step curriculum is “a drug-free model. There’s kind of a conflict between drug-free and Suboxone.” For policymakers, denying addicts the best scientifically proven treatment carries no political cost.